PL2714669T3 - Nadciśnienie i hiperurykemia - Google Patents
Nadciśnienie i hiperurykemiaInfo
- Publication number
- PL2714669T3 PL2714669T3 PL12789268T PL12789268T PL2714669T3 PL 2714669 T3 PL2714669 T3 PL 2714669T3 PL 12789268 T PL12789268 T PL 12789268T PL 12789268 T PL12789268 T PL 12789268T PL 2714669 T3 PL2714669 T3 PL 2714669T3
- Authority
- PL
- Poland
- Prior art keywords
- hyperuricemia
- hypertension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161489597P | 2011-05-24 | 2011-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2714669T3 true PL2714669T3 (pl) | 2017-09-29 |
Family
ID=47217678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12789268T PL2714669T3 (pl) | 2011-05-24 | 2012-05-22 | Nadciśnienie i hiperurykemia |
Country Status (27)
Country | Link |
---|---|
US (1) | US20140171424A1 (pl) |
EP (1) | EP2714669B1 (pl) |
JP (1) | JP5964952B2 (pl) |
KR (1) | KR101624023B1 (pl) |
CN (1) | CN103702986A (pl) |
AU (1) | AU2012258860B2 (pl) |
BR (1) | BR112013030078A2 (pl) |
CA (1) | CA2837080C (pl) |
CY (1) | CY1119156T1 (pl) |
DK (1) | DK2714669T3 (pl) |
EA (1) | EA201370247A1 (pl) |
ES (1) | ES2633762T3 (pl) |
HR (1) | HRP20171054T1 (pl) |
HU (1) | HUE033868T2 (pl) |
IL (1) | IL229537A0 (pl) |
LT (1) | LT2714669T (pl) |
MX (1) | MX348281B (pl) |
MY (1) | MY163930A (pl) |
NZ (1) | NZ618373A (pl) |
PL (1) | PL2714669T3 (pl) |
PT (1) | PT2714669T (pl) |
RS (1) | RS56225B1 (pl) |
SG (1) | SG195112A1 (pl) |
SI (1) | SI2714669T1 (pl) |
UA (1) | UA109943C2 (pl) |
WO (1) | WO2012162323A1 (pl) |
ZA (1) | ZA201308807B (pl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2217577B1 (en) | 2007-11-27 | 2014-08-06 | Ardea Biosciences, Inc. | Novel compounds and compositions and methods of use |
EP3659601A1 (en) | 2010-03-30 | 2020-06-03 | Ardea Biosciences, Inc. | Treatment of gout |
WO2011159732A1 (en) | 2010-06-15 | 2011-12-22 | Ardea Biosciences,Inc. | Treatment of gout and hyperuricemia |
CN104311452B (zh) * | 2014-09-27 | 2016-01-06 | 张远强 | 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途 |
CN104292124B (zh) * | 2014-09-27 | 2016-01-20 | 张远强 | 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途 |
KR102487604B1 (ko) * | 2020-11-06 | 2023-01-12 | 에스케이케미칼 주식회사 | 히드로플루메티아지드를 유효성분으로 포함하는 TNF-α 관련 질환 예방 또는 치료용 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
US20090054319A1 (en) * | 2005-03-17 | 2009-02-26 | Microbia, Inc. | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders |
EP2217577B1 (en) * | 2007-11-27 | 2014-08-06 | Ardea Biosciences, Inc. | Novel compounds and compositions and methods of use |
CN102186832B (zh) * | 2008-09-04 | 2014-04-02 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
-
2012
- 2012-05-22 AU AU2012258860A patent/AU2012258860B2/en not_active Ceased
- 2012-05-22 PT PT127892685T patent/PT2714669T/pt unknown
- 2012-05-22 WO PCT/US2012/039011 patent/WO2012162323A1/en active Application Filing
- 2012-05-22 PL PL12789268T patent/PL2714669T3/pl unknown
- 2012-05-22 NZ NZ618373A patent/NZ618373A/en not_active IP Right Cessation
- 2012-05-22 EP EP12789268.5A patent/EP2714669B1/en active Active
- 2012-05-22 SI SI201231005T patent/SI2714669T1/sl unknown
- 2012-05-22 CN CN201280036513.7A patent/CN103702986A/zh active Pending
- 2012-05-22 MX MX2013013655A patent/MX348281B/es active IP Right Grant
- 2012-05-22 MY MYPI2013004222A patent/MY163930A/en unknown
- 2012-05-22 HU HUE12789268A patent/HUE033868T2/en unknown
- 2012-05-22 EA EA201370247A patent/EA201370247A1/ru unknown
- 2012-05-22 KR KR1020137034028A patent/KR101624023B1/ko active IP Right Grant
- 2012-05-22 JP JP2014512951A patent/JP5964952B2/ja not_active Expired - Fee Related
- 2012-05-22 CA CA2837080A patent/CA2837080C/en not_active Expired - Fee Related
- 2012-05-22 UA UAA201315150A patent/UA109943C2/uk unknown
- 2012-05-22 SG SG2013086574A patent/SG195112A1/en unknown
- 2012-05-22 BR BR112013030078A patent/BR112013030078A2/pt not_active Application Discontinuation
- 2012-05-22 DK DK12789268.5T patent/DK2714669T3/en active
- 2012-05-22 US US14/119,599 patent/US20140171424A1/en not_active Abandoned
- 2012-05-22 RS RS20170696A patent/RS56225B1/sr unknown
- 2012-05-22 ES ES12789268.5T patent/ES2633762T3/es active Active
- 2012-05-22 LT LTEP12789268.5T patent/LT2714669T/lt unknown
-
2013
- 2013-11-21 IL IL229537A patent/IL229537A0/en unknown
- 2013-11-22 ZA ZA2013/08807A patent/ZA201308807B/en unknown
-
2017
- 2017-07-11 HR HRP20171054TT patent/HRP20171054T1/hr unknown
- 2017-07-18 CY CY20171100766T patent/CY1119156T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR101624023B1 (ko) | 2016-05-24 |
CA2837080A1 (en) | 2012-11-29 |
EP2714669A1 (en) | 2014-04-09 |
IL229537A0 (en) | 2014-01-30 |
SI2714669T1 (sl) | 2017-10-30 |
WO2012162323A1 (en) | 2012-11-29 |
US20140171424A1 (en) | 2014-06-19 |
JP5964952B2 (ja) | 2016-08-03 |
HRP20171054T1 (hr) | 2017-10-06 |
EA201370247A1 (ru) | 2014-07-30 |
KR20140023396A (ko) | 2014-02-26 |
CN103702986A (zh) | 2014-04-02 |
BR112013030078A2 (pt) | 2016-08-09 |
MY163930A (en) | 2017-11-15 |
LT2714669T (lt) | 2017-08-10 |
AU2012258860A1 (en) | 2014-01-09 |
EP2714669A4 (en) | 2015-01-07 |
DK2714669T3 (en) | 2017-08-07 |
SG195112A1 (en) | 2013-12-30 |
CY1119156T1 (el) | 2018-02-14 |
MX2013013655A (es) | 2014-08-21 |
MX348281B (es) | 2017-06-02 |
HUE033868T2 (en) | 2018-01-29 |
JP2014515376A (ja) | 2014-06-30 |
ES2633762T3 (es) | 2017-09-25 |
CA2837080C (en) | 2017-01-24 |
RS56225B1 (sr) | 2017-11-30 |
AU2012258860B2 (en) | 2015-12-03 |
ZA201308807B (en) | 2019-07-31 |
PT2714669T (pt) | 2017-07-21 |
NZ618373A (en) | 2015-10-30 |
UA109943C2 (xx) | 2015-10-26 |
EP2714669B1 (en) | 2017-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100012I1 (hu) | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók | |
IL222176B (en) | Radioprotector compounds and methods | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
HK1198433A1 (en) | N-acyldipeptide derivatives and their uses n- | |
AP4055A (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
IL229844B (en) | Anti-psgl-1 antibodies and their use | |
HK1191034A1 (en) | N-carboxyalkyl-auristatins and use thereof n- | |
EP2708532A4 (en) | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | |
EP2688588A4 (en) | FAST AND LONG-TERM IMMUNOLOGICAL THERAPEUTIC | |
ZA201308807B (en) | Hypertension and hyperuricemia | |
GB201111775D0 (en) | Compounds and uses thereof | |
EP2693879A4 (en) | MIGRASTATINES AND THEIR USES | |
LT3689878T (lt) | 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai | |
GB201119443D0 (en) | GoWinging Concept and patent | |
GB201121726D0 (en) | Compounds and uses thereof | |
GB201121551D0 (en) | Compounds and uses thereof | |
GB201117881D0 (en) | Biomarkers and uses thereof |